Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07139873 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Sponsor changed: Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Dizal Pharmaceuticalsv5 See this version in full on ClinicalTrials.gov ↗
  2. Site details revised at 1 of 2 sitesv4
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Start date changed from estimate of Sep 2025 to Sep 8, 2025v3 Show 2 more changesShow less
    • Study sites: 0 to 2
    • Start date changed from estimate of Sep 2025 to Sep 8, 2025
  4. Study title shortened, about 2 wordsv2 See this version in full on ClinicalTrials.gov ↗
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy. Primary objective of this study is to assess the efficacy using progression free survival assessed by independent review committee as primary endpoint. Approximately 250 participants are estimated to be randomized into the study.
Trial Details
NCT Number NCT07139873
Lead Sponsor Dizal Pharmaceuticals
Conditions Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment 250 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov